Deva Holding A.S.: peers
Deva Holding A.S. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Deva Holding A.S., Kamada Ltd., EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S., Pharmanutra S.p.A.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Deva Holding A.S.base DEVA.IS · 🇹🇷 TR Percentile in Healthcare Percentile in Turkey | Kamada Ltd. KMDA · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S. ECILC.IS · 🇹🇷 TR Percentile in Healthcare Percentile in Turkey | Aquestive Therapeutics, Inc. AQST · 🇺🇸 US Percentile in Healthcare Percentile in USA | Evolus, Inc. EOLS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Alpha Teknova, Inc. TKNO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Ironwood Pharmaceuticals, Inc. IRWD · 🇺🇸 US Percentile in Healthcare Percentile in USA | Pharmanutra S.p.A. PHN.MI · 🇮🇹 IT Percentile in Healthcare Percentile in Italy | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $526 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8 | $463 MAug 1, 2026 · Market data8th of 8 | $1.1 BAug 1, 2026 · Market data1st of 8 | $508 MOct 30, 2026 · Market data5th of 8 | $501 MOct 16, 2026 · Market data6th of 8 | $494 MOct 29, 2026 · Market data7th of 8 | $599 MOct 30, 2026 · Market data2nd of 8 | $593 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $517 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $180 MFY2025 · SEC3rd of 6 | —— | $45 MFY2025 · SEC5th of 6 | $297 MFY2025 · SEC1st of 6 | $41 MFY2025 · SEC6th of 6 | $296 MFY2025 · SEC2nd of 6 | $148 MFY2025 · ESEF4th of 6 | $164 M6 ranked |
| Net income (Higher is better) | —— | $20 MFY2025 · SEC3rd of 6 | —— | $-84 MFY2025 · SEC6th of 6 | $-52 MFY2025 · SEC5th of 6 | $-17 MFY2025 · SEC4th of 6 | $24 MFY2025 · SEC1st of 6 | $23 MFY2025 · ESEF2nd of 6 | $1 M6 ranked |
| Employees (Better neither way: ranked highest first) | —— | 393December 31, 2025 · Profile1st of 5 | —— | 147December 31, 2025 · Profile5th of 5 | 334December 31, 2025 · Profile2nd of 5 | 158December 31, 2025 · Profile4th of 5 | 219As on 2021 · Profile3rd of 5 | —— | 2195 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | +12.1%FY2025 · SEC2nd of 654th50th | ———— | -22.6%FY2025 · SEC6th of 610th5th | +11.6%FY2025 · SEC3rd of 653rd65th | +7.4%FY2025 · SEC4th of 643rd53rd | -15.7%FY2025 · SEC5th of 612th7th | +18.8%FY2025 · ESEF1st of 666th87th | +9.5%6 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | +11.7%FY2025 · SEC2nd of 558th55th | ———— | -2.3%FY2025 · SEC4th of 521st25th | +26.0%FY2025 · SEC1st of 578th89th | -0.7%FY2025 · SEC3rd of 525th30th | -10.3%FY2025 · SEC5th of 512th10th | ———— | -0.7%5 ranked |
| Earnings per share growth (Higher is better) | ———— | +40.0%FY2025 · SEC1st of 273rd75th | ———— | ———— | ———— | ———— | ———— | +25.9%FY2025 · ESEF2nd of 268th70th | +32.9%2 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | 42.3%FY2025 · SEC3rd of 426th49th | ———— | 58.3%FY2025 · SEC2nd of 450th72nd | 66.3%FY2025 · SEC1st of 462nd79th | 33.2%FY2025 · SEC4th of 419th40th | ———— | ———— | 50.3%4 ranked |
| Operating margin (Higher is better) | ———— | 14.5%FY2025 · SEC3rd of 681st81st | ———— | -159.5%FY2025 · SEC6th of 617th7th | -11.0%FY2025 · SEC4th of 647th26th | -41.9%FY2025 · SEC5th of 634th16th | 33.3%FY2025 · SEC1st of 696th95th | 26.0%FY2025 · ESEF2nd of 693rd91st | 1.8%6 ranked |
| Net margin (Higher is better) | ———— | 11.2%FY2025 · SEC2nd of 681st80th | ———— | -188.1%FY2025 · SEC6th of 616th6th | -17.4%FY2025 · SEC4th of 644th23rd | -42.6%FY2025 · SEC5th of 632nd16th | 8.1%FY2025 · SEC3rd of 675th70th | 15.2%FY2025 · ESEF1st of 686th85th | -4.6%6 ranked |
| Free cash flow margin (Higher is better) | ———— | 8.7%FY2025 · SEC2nd of 569th60th | ———— | -119.0%FY2025 · SEC5th of 519th7th | -15.4%FY2025 · SEC3rd of 539th18th | -24.2%FY2025 · SEC4th of 535th16th | 42.9%FY2025 · SEC1st of 598th99th | ———— | -15.4%5 ranked |
| Return on equity (Higher is better) | ———— | 7.6%FY2025 · SEC2nd of 379th68th | ———— | ———— | ———— | -22.8%FY2025 · SEC3rd of 359th27th | ———— | 30.4%FY2025 · ESEF1st of 395th92nd | 7.6%3 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | 22.9׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | ———— | 4.0×price Oct 30, 2026 · Market dataonly one with it5th3rd | ———— | 4.0×— |
| Price to sales (Better neither way: ranked highest first) | ———— | 2.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 10.4×price Oct 30, 2026 · Market data2nd of 474th89th | 1.5×price Oct 16, 2026 · Market data3rd of 425th40th | 10.8×price Oct 29, 2026 · Market data1st of 475th90th | 1.5×price Oct 30, 2026 · Market data4th of 424th40th | ———— | 6.0×4 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 1.7׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | 7.2×price Oct 29, 2026 · Market dataonly one with it77th84th | ———— | ———— | 7.2×— |
| Free cash flow yield (Higher is better) | ———— | 3.4%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | -10.4%price Oct 30, 2026 · Market data4th of 442nd20th | -9.1%price Oct 16, 2026 · Market data3rd of 444th22nd | -2.0%price Oct 29, 2026 · Market data2nd of 462nd32nd | 21.2%price Oct 30, 2026 · Market data1st of 498th96th | ———— | -5.5%4 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | ———— | 0.2×FY2025 · SEConly one with it31st22nd | ———— | ———— | 0.2×— |
| Piotroski F-score (Higher is better) | —— | —— | —— | 2 of 9FY2025 · SEC2nd of 3 | 2 of 9FY2025 · SEC2nd of 3 | 5 of 9FY2025 · SEC1st of 3 | —— | —— | 2.0 of 93 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 10 of 12FY2025 · Scorecard2nd of 6 | —— | 2 of 20FY2025 · Scorecard6th of 6 | 8 of 19FY2025 · Scorecard4th of 6 | 6 of 21FY2025 · Scorecard5th of 6 | 11 of 20FY2025 · Scorecard3rd of 6 | 5 of 5FY2025 · Scorecard1st of 6 | 49% passed6 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | 0 of 5FY2025 · Scorecard3rd of 4 | 1 of 5FY2025 · Scorecard2nd of 4 | 0 of 5FY2025 · Scorecard3rd of 4 | 5 of 6FY2025 · Scorecard1st of 4 | —— | 10% passed4 ranked |
| Growth checks (Higher is better) | —— | 6 of 6FY2025 · Scorecard1st of 6 | —— | 0 of 6FY2025 · Scorecard6th of 6 | 5 of 6FY2025 · Scorecard3rd of 6 | 2 of 6FY2025 · Scorecard4th of 6 | 1 of 6FY2025 · Scorecard5th of 6 | 2 of 2FY2025 · Scorecard1st of 6 | 58% passed6 ranked |
| Profitability checks (Higher is better) | —— | 3 of 5FY2025 · Scorecard2nd of 6 | —— | 0 of 4FY2025 · Scorecard6th of 6 | 1 of 4FY2025 · Scorecard4th of 6 | 1 of 5FY2025 · Scorecard5th of 6 | 2 of 4FY2025 · Scorecard3rd of 6 | 3 of 3FY2025 · Scorecard1st of 6 | 38% passed6 ranked |
| Financial health checks (Higher is better) | —— | 1 of 1FY2025 · Scorecard1st of 5 | —— | 2 of 4FY2025 · Scorecard4th of 5 | 1 of 3FY2025 · Scorecard5th of 5 | 3 of 4FY2025 · Scorecard2nd of 5 | 2 of 3FY2025 · Scorecard3rd of 5 | —— | 67% passed5 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | —— | 0 of 1FY2025 · Scorecard2nd of 4 | 0 of 1FY2025 · Scorecard2nd of 4 | 0 of 1FY2025 · Scorecard2nd of 4 | 1 of 1FY2025 · Scorecard1st of 4 | —— | 0% passed4 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 8.9%2026-Q1 · 13F5th of 5 | —— | 60.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 5 | 76.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5 | 16.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 5 | 92.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5 | —— | 60.1%5 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 422026-Q1 · 13F5th of 5 | —— | 1902026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5 | 1702026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 5 | 1102026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 5 | 2322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5 | —— | 1705 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | -0.4 pp2026-Q1 against 2025-Q4 · 13F4th of 5 | —— | -1.4 pp2026-Q2 against 2026-Q1 · 13F5th of 5 | +14.6 pp2026-Q2 against 2026-Q1 · 13F1st of 5 | +2.7 pp2026-Q2 against 2026-Q1 · 13F2nd of 5 | -0.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 5 | —— | -0.2 pp5 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Deva Holding A.S.: How market caps are worked out; Kamada Ltd.: How market caps are worked out; EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S.: How market caps are worked out; Aquestive Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Evolus, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Alpha Teknova, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Ironwood Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Pharmanutra S.p.A.: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Deva Holding A.S. | — | — | — |
| Kamada Ltd. | 14.5%FY2025 | 81st percentile in Healthcaremedian -7.7%, 674 companies | 81st percentile in Israelmedian -0.2%, 67 companies |
| EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S. | — | — | — |
| Aquestive Therapeutics, Inc. | -159.5%FY2025 | 17th percentile in Healthcaremedian -7.7%, 674 companies | 7th percentile in USAmedian 3.5%, 2,594 companies |
| Evolus, Inc. | -11.0%FY2025 | 47th percentile in Healthcaremedian -7.7%, 674 companies | 26th percentile in USAmedian 3.5%, 2,594 companies |
| Alpha Teknova, Inc. | -41.9%FY2025 | 34th percentile in Healthcaremedian -7.7%, 674 companies | 16th percentile in USAmedian 3.5%, 2,594 companies |
| Ironwood Pharmaceuticals, Inc. | 33.3%FY2025 | 96th percentile in Healthcaremedian -7.7%, 674 companies | 95th percentile in USAmedian 3.5%, 2,594 companies |
| Pharmanutra S.p.A. | 26.0%FY2025 | 93rd percentile in Healthcaremedian -7.7%, 674 companies | 91st percentile in Italymedian 8.8%, 101 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Deva Holding A.S. | Kamada Ltd. | EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S. | Aquestive Therapeutics, Inc. | Evolus, Inc. | Alpha Teknova, Inc. | Ironwood Pharmaceuticals, Inc. | Pharmanutra S.p.A. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $180 MSEC3rd | — | $45 MSEC5th | $297 MSEC1st | $41 MSEC6th | $296 MSEC2nd | $148 MESEF4th |
| 2024 | — | $161 MSEC3rd | — | $58 MSEC5th | $266 MSEC2nd | $38 MSEC6th | $351 MSEC1st | $125 MESEF4th |
| 2023 | — | $143 MSEC3rd | — | $51 MSEC4th | $202 MSEC2nd | $37 MSEC5th | $443 MSEC1st | — |
| 2022 | — | $129 MSEC3rd | — | $48 MSEC4th | $149 MSEC2nd | $41 MSEC5th | $411 MSEC1st | — |
| 2021 | — | $104 MSEC2nd | — | $51 MSEC4th | $100 MSEC3rd | $37 MSEC5th | $414 MSEC1st | — |
| 2020 | — | $133 MSEC2nd | — | $46 MSEC4th | $57 MSEC3rd | $31 MSEC5th | $390 MSEC1st | — |
| 2019 | — | $127 MSEC2nd | — | $53 MSEC3rd | $35 MSEC4th | — | $428 MSEC1st | — |
| 2018 | — | $114 MSEC2nd | — | $67 MSEC3rd | — | — | $347 MSEC1st | — |
| 2017 | — | $103 MSEC2nd | — | $67 MSEC3rd | — | — | $298 MSEC1st | — |
| 2016 | — | $77 MSEC2nd | — | — | — | — | $274 MSEC1st | — |
| 2015 | — | $70 MSEC2nd | — | — | — | — | $150 MSEC1st | — |
| 2014 | — | — | — | — | — | — | $76 MSEC | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Deva Holding A.S.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Kamada Ltd.KMDA · 🇮🇱 IsraelSame industry: Pharmaceutical · Similar size: $463 M market cap against $526 M · Same region: Western Asia · Ratios of the last two fiscal years on fileMarket cap $463 M (Aug 1, 2026) · revenue $180 M (year to December 2025)91 of 100 (industry or sector 50 + size 29 + country 7 + figures on file 5)In the group
- EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S.ECILC.IS · 🇹🇷 TurkeySame industry: Pharmaceutical · Similar size: $1.1 B market cap against $526 M · Same country: TurkeyMarket cap $1.1 B (Aug 1, 2026)90 of 100 (industry or sector 50 + size 25 + country 15)In the group
- Aquestive Therapeutics, Inc.AQST · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $508 M market cap against $526 M · Ratios of the last two fiscal years on fileMarket cap $508 M (Oct 30, 2026) · revenue $45 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Evolus, Inc.EOLS · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $501 M market cap against $526 M · Ratios of the last two fiscal years on fileMarket cap $501 M (Oct 16, 2026) · revenue $297 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Alpha Teknova, Inc.TKNO · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $494 M market cap against $526 M · Ratios of the last two fiscal years on fileMarket cap $494 M (Oct 29, 2026) · revenue $41 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Ironwood Pharmaceuticals, Inc.IRWD · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $599 M market cap against $526 M · Ratios of the last two fiscal years on fileMarket cap $599 M (Oct 30, 2026) · revenue $296 M (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)In the group
- Pharmanutra S.p.A.PHN.MI · 🇮🇹 ItalySame industry: Pharmaceutical · Similar size: $593 M market cap against $526 M · Ratios of the last two fiscal years on fileMarket cap $593 M (last known, Jan 5, 2024) · revenue $148 M (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)In the group
- Evotec SEEVT.DE · 🇩🇪 GermanySame industry: Pharmaceutical · Similar size: $720 M market cap against $526 M · Ratios of the last two fiscal years on fileMarket cap $720 M (Aug 1, 2026) · revenue $862 M (year to December 2024)83 of 100 (industry or sector 50 + size 28 + figures on file 5)+ Add
- Collegium Pharmaceutical, Inc.COLL · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $715 M market cap against $526 M · Ratios of the last two fiscal years on fileMarket cap $715 M (Oct 28, 2026) · revenue $781 M (year to December 2025)83 of 100 (industry or sector 50 + size 28 + figures on file 5)+ Add
- Solid Biosciences Inc.SLDB · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $713 M market cap against $526 M · Ratios of the last two fiscal years on fileMarket cap $713 M (Oct 30, 2026)83 of 100 (industry or sector 50 + size 28 + figures on file 5)+ Add
- Saudi Pharmaceutical Industries and Medical Appliances Corporation2070.SR · 🇸🇦 Saudi ArabiaSame industry: Pharmaceutical · Similar size: $995 M market cap against $526 M · Same region: Western AsiaMarket cap $995 M (Aug 1, 2026) · revenue $389 M (year to December 2021)83 of 100 (industry or sector 50 + size 26 + country 7)+ Add
- Aker BioMarine ASAKBM.OL · 🇳🇴 NorwaySame industry: Pharmaceutical · Similar size: $382 M market cap against $526 M · Ratios of the last two fiscal years on fileMarket cap $382 M (last known, Jan 5, 2024) · revenue $218 M (year to December 2025)83 of 100 (industry or sector 50 + size 28 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.